Pathology News
admin

About admin@pathologynews.com

This author has not yet filled in any details.
So far admin@pathologynews.com has created 1089 blog entries.

September 2024

Conversation with Meriem Sefta, Owkin

2024-09-30T09:00:33+00:00

In this interview, Meriem Sefta from Owkin discusses her journey from academia to her role at Owkin, where she focuses on applying AI to digital pathology. She explains how Owkin's innovative approach leverages AI to analyze digital pathology slides and link molecular and morphological data for improved diagnostics and drug discovery. Sefta highlights Owkin's partnerships with hospitals to securely access real-world clinical data, which enhances their AI models. She also discusses their CE-marked products for colorectal and breast cancer, as well as the broader impact of AI on the future of pathology, drug development, and personalized medicine.

Conversation with Meriem Sefta, Owkin2024-09-30T09:00:33+00:00

GRM Information Management and HistoWiz Build Upon Partner Relationship with Histowiz Becoming a GRM Client

2024-09-30T08:34:39+00:00

GRM Information Management of Jersey City, NJ and HistoWiz of Long Island City, NY recently announced a corporate partnership that allows both organizations to offer their clients a more comprehensive suite of pathology services; ranging from analysis and digitization to long term storage of blocks and slides. That mutually beneficial partnership has now expanded, with HistoWiz becoming a client of GRM’s pathology storage services.

GRM Information Management and HistoWiz Build Upon Partner Relationship with Histowiz Becoming a GRM Client2024-09-30T08:34:39+00:00

Aiosyn and HistoWiz Partner to Improve Kidney Disease Research Through AI-Powered Preclinical and Research Studies

2024-09-27T13:17:38+00:00

Pilot study evaluates the benefits of integrating Aiosyn’s NephroPath kidney analysis algorithms onto HistoWiz’s PathologyMap™ digital pathology platform.Aiosyn, a pioneering pathology software company specializing in AI-powered solutions for cancer and kidney disease, and HistoWiz, a leading provider of histology and slide archiving services, today announced a pilot study to evaluate the benefits of integrating Aiosyn’s NephroPath kidney analysis [...]

Aiosyn and HistoWiz Partner to Improve Kidney Disease Research Through AI-Powered Preclinical and Research Studies2024-09-27T13:17:38+00:00

AIVIS Secured In Vitro Diagnostic Certification for Its AI-Powered Quantification Solution, ‘Qanti IHC’

2025-06-03T12:25:54+00:00

On September 27, 2024, AIVIS Co., Ltd. announced that it had obtained in vitro diagnostic medical device certification from the Ministry of Food and Drug Safety (MFDS) for its AI-powered morphometric analysis solution for IHC-stained pathology slides, Qanti IHC

AIVIS Secured In Vitro Diagnostic Certification for Its AI-Powered Quantification Solution, ‘Qanti IHC’2025-06-03T12:25:54+00:00

Spatially Defined Ligand/Receptors as Potential Novel Biomarkers for Response to Immunotherapy

2024-09-27T09:23:12+00:00

The challenges that immuno-oncology researchers face can boil down to one thing: resolving tumor heterogeneity. And the answer to these challenges lies in better biomarkers. However, biomarkers themselves are heterogeneous. While a biomarker is typically defined as the presence or absence of something—a gene, an analyte, a protein marker—they encompass so much more than that.

Spatially Defined Ligand/Receptors as Potential Novel Biomarkers for Response to Immunotherapy2024-09-27T09:23:12+00:00

The Introduction to the AI Act

2024-09-26T11:00:06+00:00

This year marked a significant advancement in the regulation of AI-powered devices within the European market with the introduction of the AI Act. As the first comprehensive regulation on artificial intelligence, the AI Act has established a benchmark for future policies, shaping the direction of AI governance on a global scale. The Act applies to a wide range of AI technologies across various industries, classifying products into categories based on their assessed risk of causing harm.

The Introduction to the AI Act2024-09-26T11:00:06+00:00

HistoWiz and AIRA Matrix Collaborate to Offer Advanced AI Models on the PathologyMap™ Platform

2024-09-25T15:03:55+00:00

HistoWiz, a leader in digital pathology services, and AIRA Matrix Private Limited, a leading technology company that provides diagnostic, prognostic, and predictive AI solutions for preclinical and clinical workflows, announced at the Digital Pathology & AI Congress: USA their intent to bring AIRA Matrix’s AI tools to HistoWiz’s PathologyMap™ digital platform.

HistoWiz and AIRA Matrix Collaborate to Offer Advanced AI Models on the PathologyMap™ Platform2024-09-25T15:03:55+00:00

Lausanne Researchers Combine 10x Genomics’ Chromium and Xenium for Novel Insights into Resistance and Potential Therapeutics for Brain Cancer

2025-06-26T16:04:25+00:00

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that its Chromium Single Cell Gene Expression and Xenium In Situ platforms were used in a publication – featured on the cover of Cancer Cell – that sheds light on the role of fibrotic scars in glioblastoma treatment recurrence.

Lausanne Researchers Combine 10x Genomics’ Chromium and Xenium for Novel Insights into Resistance and Potential Therapeutics for Brain Cancer2025-06-26T16:04:25+00:00

Building AI Models from Whole Slide Images

2024-09-24T11:20:35+00:00

While data is an essential component in developing an AI diagnostic [see blog 2], its power is only realized with an algorithm that analyzes and learns from the data. An AI diagnostic model consists of a set of instructions that process a whole slide image (WSI) and make a prediction, such as screening for microsatellite instability (MSI). To create this model, it must learn from examples, use different layers of understanding (like a pathologist zooming in and out), and make mistakes before learning to improve – not unlike a human studying a new task. But enough of this abstract talk of models. This blog will illustrate how multiple models come together in building an AI diagnostic like Owkin’s MSIntuit CRC.

Building AI Models from Whole Slide Images2024-09-24T11:20:35+00:00

HistoWiz and Molecular Instruments® Collaborate to Advance ISH Services Powered by HCR™ RNA-ISH

2024-09-23T15:01:12+00:00

HistoWiz, a leading provider of histology and slide archiving services, and Molecular Instruments® (MI), the inventor of the HCR™ imaging technology, announce a new co-marketing partnership to integrate HistoWiz’s automated histology and digitized pathology solutions with MI’s HCR brand products. This provides researchers with clinical-grade performance for their in situ hybridization (ISH), immunohistochemistry (IHC), and immunofluorescence (IF) assays.

HistoWiz and Molecular Instruments® Collaborate to Advance ISH Services Powered by HCR™ RNA-ISH2024-09-23T15:01:12+00:00
Go to Top